Member access

4-Traders Homepage  >  Shares  >  Nyse MKT  >  Protalix BioTherapeutics Inc.    PLX   US74365A1016

 SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse Mkt
01/21/2015 01/22/2015 01/23/2015 01/26/2015 01/27/2015 Date
2.18(c) 2.06(c) 1.99(c) 2(c) 2.09 Last
100 370 234 782 204 427 171 255 73 872 Volume
-2.24% -5.50% -3.40% +0.50% +4.50% Change
More quotes
Company
Protalix Biotherapeutics, Inc. engages in the development and commercialization of recombinant therapeutic proteins based on ProCellEx plant cell based expression system.It offers Taliglucerase alfa injections under the brand name Elelyso, an enzyme replacement therapy for Gaucher disease.Its drug... 
More about the company
Surperformance© ratings of Protalix BioTherapeutics I
Trading Rating : Investor Rating :
More Ratings
Chart PROTALIX BIOTHERAPEUTICS I
Duration : Period :
Protalix BioTherapeutics I Technical Analysis Chart | PLX | US74365A1016 | 4-Traders
Full-screen chart
Financials ($)
Sales 2013 15,8 M
EBIT 2013 -19,9 M
Net income 2013 -19,0 M
Debt 2013 -
Yield 2013 -
Sales 2014 35,8 M
EBIT 2014 -12,9 M
Net income 2014 -4,70 M
Debt 2014 -
Yield 2014 -
PER 2013 -
PER 2014
Capi. / Sales 2013 11,9x
Capi. / Sales 2014 5,23x
Capitalization 187 M
More Financials
Latest news on PROTALIX BIOTHERAPEUTICS I
01/08 PROTALIX BIOTHERAPEUTICS : jumps on positive Fabry disease trial results
01/08 PROTALIX BIOTHERAPEUTICS : Other Events (form 8-K)
01/08 Protalix BioTherapeutics Reports Positive Interim Data From Phase I/II Clinic..
01/05 MONDAY SECTOR LEADERS : Biotechnology, Drugs
01/05 Protalix BioTherapeutics to Present at the 2015 J.P. Morgan Healthcare Confer..
01/05 PROTALIX BIOTHERAPEUTICS : Results of Operations and Financial Condition, Other ..
01/05 Protalix BioTherapeutics Announces New Strategy for Accelerated Growth
2014 PROTALIX BIOTHERAPEUTICS : posts 3Q loss
More news
Sector news Biotechnology & Medical Research - NEC
02:37p PUMA BIOTECHNOLOGY : Closes $218 Million Public Offering of Common Stock
08:01a INCYTE : to Report Fourth Quarter/Year-End 2014 Financial Results on February 12
01/23 INCYTE : Earns $25 Million Milestone as Jakavi® (ruxolitinib) Recommended for Ap..
Plus d'actualités du secteur Biotechnology & Medical Research - NEC
Comments 
Advertisement
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF